With managment describing the firm as redefining the delivery of biologics more efficiently and cost-effectively, Elektrofi is a biotechnology company addressing improving the administration of a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. The MIT founded, biotechnology company addresses particularly the formulation, development and delivery of ultra-high concentration biologics. The firm's assembled team has devloped a proprietary delivery platform - designated elektroject - engineering high-concentration, low-viscosity protein formulations capable of being administered in small volumes via simple subcutaneous injection rather than hours-long intravenous infusion. The approach replaces the long period infusions into quick and efficient injections. - a transformation that does not only replace IV infusions with injections but majorly improves patient comfort and hospital efficiency. In the Spring 2019, it had been announced that LEO Pharma and Elektrofi would expand their two-year partnership - that had been formed in 2017 - to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology. This breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions.
